Page 149 - Haematologica Vol. 110 - January 2025

ARTICLE - Immune microenvironment in nodal PTCL
P. Stephan et al.
syndrome patients. J Invest Dermatol. 2019;139(3):725-728.
40. Nakamura K, Casey M, Oey H, et al. Targeting an adenosine-
mediated “don’t eat me signal” augments anti-lymphoma immunity by anti-CD20 monoclonal antibody. Leukemia. 2020;34(10):2708-2721.
41. Yang R, Elsaadi S, Misund K, et al. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade. J Immunother Cancer. 2020;8(1):e000610.
42. Perry C, Hazan-Halevy I, Kay S, et al. Increased CD39 expression on CD4(+) T lymphocytes has clinical and prognostic significance in chronic lymphocytic leukemia. Ann Hematol. 2012;91(8):1271-1279.
43. Aroua N, Boet E, Ghisi M, et al. Extracellular ATP and CD39
activate cAMP-mediated mitochondrial stress response to promote cytarabine resistance in acute myeloid Leukemia. Cancer Discov. 2020;10(10):1544-1565.
44. Li XY, Moesta AK, Xiao C, et al. Targeting CD39 in cancer reveals an extracellular ATP- and inflammasome-driven tumor immunity. Cancer Discov. 2019;9(12):1754-1773.
45. Hilchey SP, Kobie JJ, Cochran MR, et al. Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine- mediated T cell hyporesponsiveness. J Immunol. 2009;183(10):6157-6166.
46. Sonigo G, Bozonnat A, Dumont M, et al. Involvement of the CD39/CD73/adenosine pathway in T-cell proliferation and NK cell-mediated antibody-dependent cell cytotoxicity in Sezary syndrome. Blood. 2022;139(17):2712-2716.
Haematologica | 110 January 2025
141